



→ OMPs IN THE **EU AND SPAIN**




→ 2023



→ OMPs REIMBURSED IN SPAIN

OMPs REIMBURSED BY THERAPEUTICAL AREA




78 OMPs are currently reimbursed by the NHS


49% (38) OMPs restrictedly reimbursed (with restricted indications or unreimbursed indications)

→ % REIMBURSED

OMPs WITH MARKETING AUTHORISATION REIMBURSED BY THE NHS 2019 - 2023



OMPs WITH NC REIMBURSED BY THE NHS 2019 - 2023




→ AVERAGE WAITING TIME


MONTHS BETWEEN NC AND INCORPORATION INTO THE NHS




→ OMPs **NOT REIMBURSED IN SPAIN**



NUMBER OF OMPs NOT REIMBURSED BY YEAR OF NC



NUMBER OF OMPs NOT REIMBURSED BY THERAPEUTIC AREA




→ OMPs WITH MA **PENDING TO ARRIVE IN SPAIN**




→ % OMPs WITH MA WITHOUT NC




WAITING TIME SINCE MA



BY THERAPEUTIC AREA



→ **ADVANCED THERAPIES** WITH ORPHAN DESIGNATION



→ **ADVANCED THERAPIES** WITH MA, NC AND REIMBURSING 2015-2023



Note: For the preparation of this report it has not been possible to take into account drugs that are available in Spain under specific situations and special authorisations within the framework of Royal Decree 1015/2009 (compassionate use, use under conditions other than those authorised or access to foreign medicines), as the data were not available.

\*Aggregated data as of 31 December 2023